256 related articles for article (PubMed ID: 18303475)
21. Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
Fiorentini G; Filippeschi M; Turrisi G; Mambrini A; Giannessi PG; D'Alessandro M; Rossi S; Dentico P; Guadagni S; Cantore M; Madrigali A
In Vivo; 2009; 23(2):317-21. PubMed ID: 19414421
[TBL] [Abstract][Full Text] [Related]
22. [Intraperitoneal chemotherapy for ovarian cancer].
Noma J; Yoshida N
Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick RL; Myers CE; Bungay PM; DeVita VT
Cancer Treat Rep; 1978 Jan; 62(1):1-11. PubMed ID: 626987
[TBL] [Abstract][Full Text] [Related]
24. Intraperitoneal chemotherapy: a reemerging approach in the treatment of ovarian cancer.
Drake B
J Infus Nurs; 2009; 32(6):314-22. PubMed ID: 19918140
[TBL] [Abstract][Full Text] [Related]
25. Intraperitoneal chemotherapy in the treatment of ovarian cancer.
Kavanagh JJ
J Surg Oncol; 2007 Dec; 96(7):541-2. PubMed ID: 17654524
[No Abstract] [Full Text] [Related]
26. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery (cs) and hyperthermic intraperitoneal chemotherapy (hipec) in treatment of peritoneal surface malignances: report of a phase II clinical study.
Asero S; Caruso M; Vallone N; Luciani AG; Lombardo V; Terranova G; Ettore G; Giannone G
In Vivo; 2009; 23(4):645-7. PubMed ID: 19567402
[TBL] [Abstract][Full Text] [Related]
28. Consolidation therapy in ovarian cancer: where do we stand?
Dearnley DD; McMeekin DS
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):3-7. PubMed ID: 16493252
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
Di Giorgio A; Naticchioni E; Biacchi D; Sibio S; Accarpio F; Rocco M; Tarquini S; Di Seri M; Ciardi A; Montruccoli D; Sammartino P
Cancer; 2008 Jul; 113(2):315-25. PubMed ID: 18473354
[TBL] [Abstract][Full Text] [Related]
30. The role of intraperitoneal chemotherapy in ovarian cancer.
Markman M
Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249
[No Abstract] [Full Text] [Related]
31. Nursing perspectives on intraperitoneal chemotherapy.
Hoff ST
J Intraven Nurs; 1991; 14(5):309-14. PubMed ID: 1748914
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal chemotherapy in the management of malignant disease.
Markman M
Expert Rev Anticancer Ther; 2001 Jun; 1(1):142-8. PubMed ID: 12113122
[TBL] [Abstract][Full Text] [Related]
33. Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer.
Naumann RW; Sukumvanich P; Edwards RP
Gynecol Oncol; 2009 Jul; 114(1):37-41. PubMed ID: 19410281
[TBL] [Abstract][Full Text] [Related]
34. Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life.
Alberts DS; Delforge A
Semin Oncol; 2006 Dec; 33(6 Suppl 12):S8-17. PubMed ID: 17223445
[TBL] [Abstract][Full Text] [Related]
35. Intraperitoneal chemotherapy for epithelial ovarian cancer.
Alhayki M; Hopkins L; Le T
Obstet Gynecol Surv; 2006 Aug; 61(8):529-34. PubMed ID: 16842633
[TBL] [Abstract][Full Text] [Related]
36. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
Zeimet AG; Reimer D; Radl AC; Reinthaller A; Schauer C; Petru E; Concin N; Braun S; Marth C
Anticancer Res; 2009 Jul; 29(7):2803-8. PubMed ID: 19596965
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer.
Markman M
Semin Oncol; 2006 Dec; 33(6 Suppl 12):S3-7. PubMed ID: 17223444
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
39. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.
Vergote I; Amant F; Leunen K; Cadron I; Van Gorp T; Neven P; Berteloot P
Oncologist; 2008 Apr; 13(4):410-4. PubMed ID: 18448555
[TBL] [Abstract][Full Text] [Related]
40. Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
Trimble EL; Thompson S; Christian MC; Minasian L
Oncologist; 2008 Apr; 13(4):403-9. PubMed ID: 18448554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
